drugset / Trial / NCT07390864

Ergometrine Versus Carbetocin to Decrease Blood Loss in Myomectomy

NCT07390864

RandomizedParallel-groupDouble-blindPrevention

Summary

The goal of this randomized clinical trial is to determine whether intramyometrial ergometrine injection or intramyometrial carbetocin injection is more effective in reducing blood loss during and after abdominal myomectomy in women undergoing surgery for symptomatic uterine fibroids. The main questions it aims to answer are: Does intramyometrial ergometrine reduce intraoperative and postoperative blood loss during abdominal myomectomy? Does intramyometrial carbetocin reduce intraoperative and postoperative blood loss during abdominal myomectomy? Is there a difference between the two drugs in the need for blood transfusion and postoperative hemoglobin drop? Researchers will compare intramyometrial ergometrine injection with intramyometrial carbetocin injection to see which intervention is more effective in controlling surgical bleeding and improving surgical outcomes. Participants will: Undergo abdominal myomectomy for uterine fibroids Receive either intramyometrial ergometrine or intramyometrial carbetocin during surgery Be monitored for intraoperative blood loss, postoperative blood loss, hemoglobin changes, and need for blood transfusion

Timeline

Start
2026-01-18
Primary completion
2026-07-30
Completion
2026-08-30

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Carbetocin Peptide Other
Comparator Methylergonovine Small molecule Other

Indications